Blog

Targeting claudins in pancreatic cancer shows promise – ESMO

ESMO/LinkedIn

Dec 10, 2024, 17:32

Targeting claudins in pancreatic cancer shows promise – ESMO

ESMO – European Society for Medical Oncology posted the following on LinkedIn:

“IBI343, an anti-claudin 18.2 antibody-drug conjugate, shows promise in treating patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have positive CLDN18.2 expression and have failed or are intolerant to standard treatments. The updated data from the study presented at ESMOAsia24 indicates that IBI343 has a favorable safety profile and encouraging efficacy. Targeting claudins is a significant step forward in the pursuit of precision oncology.

To learn more about these results, read the ESMO Daily Reporter article.”

advanced PDAC Antibody drug conjugates Cancer research Claudin-18.2 ESMO ESMOASIA24 IBI343 oncology breakthroughs Pancreatic Cancer Precision Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage